Kalvista Pharmaceuticals Inc.
10/04/2024 | Press release | Distributed by Public on 10/04/2024 14:06
Proxy Results Form 8 K
Item 5.07 Submission of Matters to a Vote of Security Holders.
On October 3, 2024, KalVista Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders ("Annual Meeting") and the following proposals were adopted:
1. Election of two Class III directors, William Fairey and Nancy Stuart (each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified):
|
Nominees |
Shares For |
Shares Against |
Shares Abstaining |
Broker Non-Votes |
||||
|
William Fairey |
30,169,349 |
872,398 |
33,171 |
8,328,823 |
||||
|
Nancy Stuart |
19,324,277 |
11,717,484 |
33,157 |
8,328,823 |
2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025:
|
Shares For |
Shares Against |
Shares Abstaining |
Broker Non-Votes |
|||
|
39,323,443 |
46,858 |
33,440 |
0 |
3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:
|
Shares For |
Shares Against |
Shares Abstaining |
Broker Non-Votes |
|||
|
26,578,805 |
4,459,363 |
36,750 |
8,328,823 |